First R-QFII manager based outside Greater China to obtain CSSF approval for a R-QFII UCITS-compliant product
Arendt & Medernach’s teams in Luxembourg, London and Hong Kong have advised Ashmore Investment Management throughout the process leading up to the approval by the Luxembourg regulator (CSSF) of the first Luxembourg R-QFII UCITS managed by a R-QFII manager based outside Greater China.
Earlier this year, Ashmore became the first manager based outside Greater China to be granted a R-QFII licence by the authorities of the People’s Republic of China (PRC). In addition, Ashmore’s Luxembourg R-QFII UCITS has been authorised by the CSSF to invest, subject to final approval by the PRC authorities, directly up to 100 per cent of its net assets in debt instruments traded on the China Interbank Bonds Market (CIBM), which is unprecedented…
Click on the link below to read the rest of the Arendt & Medernach briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Arendt & Medernach
Briefings from Arendt & Medernach
The Luxembourg Budget law, abolition of the witholding tax system and a new circular on benefits-in-kind, plus more.
The CSSF has issued a new Circular 15/601 relating to the ratio increase notification procedure laid down in Article 94(1)(g)(ii) of Directive 2013/36/EU (CRD IV).